MeiraGTx Holdings plc (MGTX)
| Market Cap | 917.40M +73.6% |
| Revenue (ttm) | 81.39M +144.6% |
| Net Income | -114.20M |
| EPS | -1.42 |
| Shares Out | 92.57M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 31,797 |
| Open | 9.70 |
| Previous Close | 9.90 |
| Day's Range | 9.62 - 9.86 |
| 52-Week Range | 4.55 - 11.85 |
| Beta | 1.24 |
| Analysts | Strong Buy |
| Price Target | 24.57 (+147.93%) |
| Earnings Date | May 26, 2026 |
About MGTX
MeiraGTx Holdings plc, a clinical-stage genetic medicines company, focusing on developing treatments for patients with serious diseases. The company develops various therapies for ocular diseases, including inherited retinal diseases and large degenerative ocular diseases; neurodegenerative diseases; and xerostomia. It is also develops AAV-AQP1 for radiation-induced grade 2/3 radiation-induced xerostomia, as well as for Sjogren’s syndrome; AAV-GAD in Phase 2 trial for Parkinson’s disease; AAV-RPE65 in Phase 2 trial for RPE65-associated retinal ... [Read more]
Financial Performance
In 2025, MeiraGTx Holdings's revenue was $81.39 million, an increase of 144.57% compared to the previous year's $33.28 million. Losses were -$114.20 million, -22.73% less than in 2024.
Financial StatementsAnalyst Summary
According to 7 analysts, the average rating for MGTX stock is "Strong Buy." The 12-month stock price target is $24.57, which is an increase of 147.93% from the latest price.
News
MeiraGTx price target raised to $30 from $26 at Piper Sandler
Piper Sandler raised the firm’s price target on MeiraGTx (MGTX) to $30 from $26 and keeps an Overweight rating on the shares following the company’s long-term data update in xerostomia…
MeiraGTx price target raised to $24 from $16 at RBC Capital
RBC Capital raised the firm’s price target on MeiraGTx (MGTX) to $24 from $16 and keeps an Outperform rating on the shares. The company’s 3-year follow-up data from the Phase…
MeiraGTx announces three-year data from Phase 1 AQUAx study
MeiraGTx (MGTX) announced positive three-year data from the completed Phase 1 AQUAx study of AAV-hAQP1 for the treatment of grade 2/3 late radiation-induced xerostomia. “Today we are very pleased to…
MeiraGTx Holdings Transcript: KOL event
Three-year phase I data for AAV-AQP1 in persistent RIX show robust, durable efficacy and safety, with transformative, disease-modifying effects and high physician and payer support. The therapy targets a large, concentrated market, with pivotal data and BLA filing expected in 2027 and a U.S. launch in 2028.
MeiraGTx Announces Pricing of $100 Million Offering of Ordinary Shares
LONDON and NEW YORK, April 16, 2026 (GLOBE NEWSWIRE) -- MeiraGTx Holdings plc (Nasdaq: MGTX), a vertically integrated, clinical-stage genetic medicines company, today announced the pricing of an under...
MeiraGTx announces acquisition of bota-vec for treatment of XLRP
MeiraGTx (MGTX) announced that it has entered into an asset purchase agreement with Johnson & Johnson (JNJ) to acquire all interests in bota-vec for the treatment of X-linked Retinitis Pigmentosa,…
MeiraGTx Announces the Acquisition of Botaretigene Sparoparvovec (bota-vec) for the Treatment of X-linked Retinitis Pigmentosa (XLRP)
LONDON and NEW YORK, April 16, 2026 (GLOBE NEWSWIRE) -- MeiraGTx Holdings plc (Nasdaq: MGTX), a vertically integrated, clinical-stage genetic medicines company, today announced that it has entered int...
MeiraGTx Announces Positive Three-year Data from the Phase 1 AQUAx Clinical Study of AAV-hAQP1 for the Treatment of Grade 2/3 Late Radiation-Induced Xerostomia
LONDON and NEW YORK, April 16, 2026 (GLOBE NEWSWIRE) -- MeiraGTx Holdings plc (NASDAQ: MGTX), a vertically integrated, clinical-stage genetic medicines company, today announced positive three-year dat...
MeiraGTx to Present 3-Year Data from the Phase 1 AQUAx Clinical Study of AAV-hAQP1 for the Treatment of Grade 2/3 Radiation-Induced Xerostomia on Thursday, April 16, 2026
- Presentation to include 3-year data from all cohorts of the Phase 1 AQUAx Clinical Study - Cohort-level data and individual patient data from bilateral and unilateral cohorts will be presented for b...
MeiraGTx price target lowered to $18 from $20 at Evercore ISI
Evercore ISI analyst Gavin Clark-Gartner lowered the firm’s price target on MeiraGTx (MGTX) to $18 from $20 and keeps an Outperform rating on the shares. The firm adjusted targets for…
MeiraGTx price target lowered to $26 from $30 at Piper Sandler
Piper Sandler lowered the firm’s price target on MeiraGTx (MGTX) to $26 from $30 and keeps an Overweight rating on the shares following a FY25 update. The firm continues to…
MeiraGTx price target raised to $16 from $14 at BofA
BofA analyst Alec Stranahan raised the firm’s price target on MeiraGTx (MGTX) to $16 from $14 and keeps a Buy rating on the shares. The FDA’s Breakthrough Therapy Designation for…
MeiraGTx Announces FDA Breakthrough Therapy Designation for AAV2-hAQP1 for the Treatment of Grade 2 and Grade 3 Radiation-Induced Xerostomia (RIX) and Reports Fourth Quarter and Full Year 2025 Financial and Operational Results
FDA granted Breakthrough Therapy Designation for AAV2-hAQP1 for the treatment of Grade 2 and Grade 3 late xerostomia caused by radiotherapy for cancers of the upper aerodigestive tract MeiraGTx to hol...
MeiraGTx Holdings Transcript: RBC Capital Markets Virtual Ophthalmology Conference
The company highlighted late-stage ophthalmology programs for inherited retinal diseases, leveraging advanced gene therapy platforms and strong KOL relationships. Key partnerships with J&J and Lilly are advancing global filings, while a deep pipeline and innovative manufacturing support expansion into both rare and large indications.
MeiraGTx and ZipBio sign exclusive license agreement for geographic atrophy
MeiraGTx (MGTX) signed an exclusive license agreement with ZipBio, a biotechnology company pioneering AI-driven protein therapeutics. Under the agreement, MeiraGTx will receive exclusive rights to Zip...
ZipBio and MeiraGTx Enter into Exclusive License Agreement to Advance First-in-Class AAV Gene Therapy for Geographic Atrophy
BOSTON, Feb. 3, 2026 /PRNewswire/ -- ZipBio, a biotechnology company pioneering AI-driven protein therapeutics, announced an exclusive license agreement with MeiraGTx Holdings plc (Nasdaq: MGTX), a ve...
MeiraGTx price target lowered to $14 from $15 at BofA
BofA lowered the firm’s price target on MeiraGTx (MGTX) to $14 from $15 and keeps a Buy rating on the shares. The firm is updating its price targets for U.S…
MeiraGTx initiated with a Buy at H.C. Wainwright
H.C. Wainwright analyst Mitchell Kapoor initiated coverage of MeiraGTx (MGTX) with a Buy rating and $20 price target The firm has conviction that AAV-AQP1 for radiation-induced xerostomia is one of…
Graviton Bioscience to Present Selective ROCK2 Obesity Data at 8th Annual Evercore HealthCONx Conference
NEW YORK , Nov. 20, 2025 /PRNewswire/ -- Graviton Bioscience Corporation, a clinical-stage biotechnology company developing selective ROCK2 inhibitors for metabolic, inflammatory, fibrotic, and centra...
MeiraGTx sees cash runway into 2H27
As of September 30, 2025, MeiraGTx (MGTX) had cash and cash equivalents of approximately $14.8 million, as well as $2.8 million in receivables due from Johnson & Johnson Innovative Medicine…
MeiraGTx Reports Third Quarter 2025 Financial and Operational Results
LONDON and NEW YORK, Nov. 13, 2025 (GLOBE NEWSWIRE) -- MeiraGTx Holdings plc (Nasdaq: MGTX), a vertically integrated, clinical-stage genetic medicines company, today announced financial and operationa...
MeiraGTx price target raised to $30 from $28 at Piper Sandler
Piper Sandler analyst Allison M. Bratzel raised the firm’s price target on MeiraGTx (MGTX) to $30 from $28 and keeps an Overweight rating on the shares following the news that…
Eli Lilly signs deal for MeiraGTx's gene therapy for severe eye disease
MeiraGTx Holdings has signed a deal with Eli Lilly , potentially worth over $475 million, granting the pharma giant rights to its experimental gene therapy for a rare, inherited disorder that causes s...
MeiraGTx enters strategic collaboration with Eli Lilly
MeiraGTx (MGTX) announced a broad strategic collaboration in the area of ophthalmology with Eli Lilly (LLY). MeiraGTx will grant Lilly worldwide exclusive rights to its AAV-AIPL1 program for treatment...
MeiraGTx Enters into Strategic Collaboration with Eli Lilly and Company to Develop and Commercialize Genetic Medicines in Ophthalmology
LONDON and NEW YORK, Nov. 10, 2025 (GLOBE NEWSWIRE) -- MeiraGTx Holdings plc (Nasdaq: MGTX), a vertically integrated, clinical stage genetic medicines company, today announced a broad strategic collab...